Inhalation Sciences to present FDA-funded DissolvIt evaluation study results at industry conferences

• Inhalation Sciences will present results from an FDA-funded evaluation study of its DissolvIt platform at conferences in August–October 2026.
• Results have not yet been presented; first disclosure is scheduled for Aug. 26–27, followed by meetings in September and October.
• Study findings support DissolvIt as a biorelevant in vitro dissolution approach with potential to improve translation from preclinical work to clinical outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhalation Sciences Sweden AB published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.